

## Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

**Supplementary table 1.**

| Baseline characteristics of study population according to the age-specific GLOBE-score thresholds |                                 |                            |
|---------------------------------------------------------------------------------------------------|---------------------------------|----------------------------|
|                                                                                                   | GLOBE standard risk<br>(n=1499) | GLOBE high risk<br>(n=247) |
| Age at diagnosis (years) , mean (SD)                                                              | 53.9 (11.9)                     | 53 (12.3)                  |
| Gender (Female), n (%)                                                                            | 1330 (88.7)                     | 215(87.1)                  |
| Year of diagnosis, median (Q1-Q3)                                                                 | 2010 (2006-2013)                | 2008 (2004-2011)           |
| Follow up duration (years), median (Q1-Q3)                                                        | 6 (4-10)                        | 6 (4-9)                    |
| AMA positive, n (%)                                                                               | 420 (84.7)                      | 57(85.2)                   |
| ANA and/or SMA positive, n (%)                                                                    | 477(28.1)                       | 56(23.1)                   |
| ALP x UNL, median (Q1-Q3)                                                                         | 1.8 (1.3-2.9)                   | 2.7 (1.9-4.4)              |
| AST x UNL, median (Q1-Q3)                                                                         | 1.4 (1.0-2.3)                   | 2.0(1.2-2.8)               |
| Bilirubin x UNL, median (Q1-Q3)                                                                   | 0.5 (0.4-0.7)                   | 1.0 (0.8-1.5)              |
| Albumin x LLN, median (Q1-Q3)                                                                     | 1.2 (1.1-1.3)                   | 1.1 (1.0-1.1)              |
| Platelet count $\times 10^3 /\text{mm}^3$ , median (Q1-Q3)                                        | 275 (223-321)                   | 179 (137-241)              |
| Histological stage III-IV, n (%)                                                                  | 249(16.6)                       | 125(50.6)                  |

**Supplementary figure-1**

